Our Secondaries Portfolio

A track record of early conviction and quiet access

Atomberg

We invested because of the strong PMF, high operating leverage, and the founder's edge in building at the intersection of hardware and consumer.
Co-investors: A91 Partners, Jungle Ventures, Steadview Capital, Temasek

We invested because of the company's leadership in the India-to-the-world story, breakout D2C brand presence, high NPS, and massive underserved TAM in Ayurveda.
Co-investors: Fireside Ventures, Jungle Ventures, Anicut Capital

The Ayurveda Experience

We invested because of the strong, resilient team building India’s largest IP ecosystem with a long-term lens, deep consumer insight, and consistently high NPS across products.
Co-investors: Krafton, Omidyar Network, Nexus Venture Partners, Jungle Ventures

Pratilipi

We invested because of the known and credible founders, early GTM strength, and tailwinds in India's shift to employer-led healthcare.
Co-investors: Elevation Capital, General Catalyst, Khosla Ventures, Y Combinator

Loop Health

*The above portfolio reflects Forj Fund 0 — the founder’s personal investing journey, built over half a decade through direct deals and syndicates across founder, employee, and early investor secondaries. It showcases early conviction, proprietary access, and the instinct to back breakout companies before they become obvious.

Forj Fund 1 will formally launch in Q3 2025 as the institutional evolution of Fund 0’s strategy — with sharper execution, a structured fund model, and aligned capital. With an anchor LP onboard, first close is underway and the inaugural deal is expected in Q4 2025.